CLAIMS

What is claimed is:

1. Use of at least one anti-ApoE antibody in the manufacture of a medicament for reversing at least one symptom or sign of Aβ~~ß~~ plaque associated symptoms in a subject having Alzheimer's disease, Lewy body dementia, or cerebral amyloid angiopathy.

2. The use according to claim 1, wherein a symptom or sign of Aβ~~ß~~ plaque associated symptoms includes impaired cognitive function, altered behavior, abnormal language function, emotional dysregulation, seizures, impaired nervous system structure or function, and an increased risk of development of Alzheimer's disease or cerebral amyloid angiopathy.

3. The use according to claim 1, wherein the anti-ApoE antibody binds an epitope within the ApoE coding sequence.

~~4. The use according to claim 1, wherein the administration comprises an effective systemic route of administration.~~

~~5. The use according to claim 1, wherein the administration comprises an effective local route of administration including directly within the central nervous system.~~

~~6~~4. Use of at least one anti-ApoE antibody in the manufacture of a medicament for decreasing the amyloid plaque load in the brain of a subject having Alzheimer's disease, Lewy body dementia, or cerebral amyloid angiopathy.

~~7~~5. The use according to claim ~~6~~4, wherein the anti-ApoE antibody binds an epitope within the ApoE coding sequence.

~~8. The use according to claim 6, wherein the administration comprises an effective systemic route of administration.~~

~~9. The use according to claim 6, wherein the administration comprises an effective local route of administration including directly within the central nervous system.~~

~~106~~. The use according to claim ~~64~~, wherein the amyloid plaque loads are decreased in the hippocampus.

~~117~~. The use according to claim ~~64~~, wherein the amyloid plaque loads are decreased in the cortex.